ERBB2 and breast cancer: In light of such evidence, the present review aimed to investigate the administration route preferences’ (SC or IV) among patients and HCPs (doctors, nurses, psychologists and others); and to investigate the healthcare resources utilization (quality and quantity) for each route of administration (SC or IV) for treating the patients with HER2-positive BC.